Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Camrelizumab and Apatinib Sequential Therapy in Untreated Advanced SCLC
NCT04453930Phase 2Unknown
- Sponsor
- Peking Union Medical College Hospital
- Start
- Jun 2020
- Primary completion
- Jun 2023
- Modality
- Small Molecules, Immune Checkpoint Inhibitors
- Countries
- 1
01
Overview
A Phase 2 trial of camrelizumab, Rivoceranib in small cell lung cancer (SCLC), sponsored by Peking Union Medical College Hospital. Status: unknown.
02
Drugs
camrelizumabRivoceranib
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on NCT04453930.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04453930.